Boehringer Ingelheim, Lilly Reveal CHMP Gives Positive Opinion For Empagliflozin

March 21, 2014 12:31 PM

20 0

( - Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. ( LLY ) announced a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency, recommending approval of empagliflozin, an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D).

"The CHMP positive opinion brings us a step closer to having a potential new treatment option for adults in Europe with type 2 diabetes," said Prof. Klaus Dugi, corporate senior vice president medicine, Boehringer Ingelheim. "If approved, empagliflozin would be the third product approved in Europe a...

Read more

To category page